Intacoxia P 60mg/325mg Tablet is a combination medication containing Etoricoxib 60mg and Paracetamol 325mg, indicated for the management of acute pain and inflammation associated with musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, and postoperative pain. Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, provides anti-inflammatory and analgesic effects by reducing the synthesis of prostaglandins involved in pain and inflammation, while Paracetamol acts centrally to alleviate pain and reduce fever through inhibition of prostaglandin synthesis in the central nervous system. This dual mechanism offers enhanced analgesic efficacy with a potentially lower risk of gastrointestinal adverse effects compared to non-selective NSAIDs. Intacoxia P is typically administered orally, with dosage tailored according to the severity of symptoms and patient response, under medical supervision. Caution is advised in patients with a history of cardiovascular disease, hepatic or renal impairment, and gastrointestinal disorders. Common adverse effects may include gastrointestinal discomfort, dizziness, and elevated liver enzymes. It is contraindicated in patients with hypersensitivity to Etoricoxib, Paracetamol, or other NSAIDs, and should be used cautiously during pregnancy and lactation. Regular monitoring and adherence to prescribed dosing are essential to minimize risks and optimize therapeutic outcomes.